Table 1.
Summary of clinical characteristics of all patients with invasive fungal infections
|
IFN-γ treated patients | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | Pathogens | n= | Site of nfection | n= | Underlying illness | n= | Antifungal therapy | n= | Outcome | n= |
| 49.6 ± SD19.8 |
C. albicans |
3 |
Candidaemia |
2 |
Stem cell transplantation for AML |
1 |
Anidulafungin |
1 |
Cured without further infectious complications |
2 |
|
BMI |
Candida spp |
2 |
Candidaemia Endocarditis |
1 |
Sarcoidosis treated with prednisone and azathioprin |
1 |
Fluconazole |
1 |
Lost to follow up after discharge from hospital |
1 |
| 22.9 ± SD6.9 |
A. fumigatus |
2 |
Pulmonary aspergilllosis |
3 |
First remission induction chemotherapy for AML |
1 |
L-AMB + Voriconazole |
1 |
Slight reduction hepatic lesions |
1 |
|
Gender |
C. tropicalis |
1 |
Osteomeyelitis |
1 |
ICD, Streptococcus sanguis endocarditis, aorta valve replacement with bioprosthesis |
1 |
Voriconazole + Anidulafungin |
1 |
Cured but complicated with mycotic cerebral aneurysms |
1 |
| F: 5 M: 3 |
A. fumigatus+ M. genavese |
1 |
Hepatic abcess |
1 |
persistent pulmonary cavity after radiotherapy for a T1N0M0 lungcarcinoma |
1 |
Itraconasole, L-AMB, Voriconazole |
1 |
Cured from candidemia episode, 4 months later unrelated bacterial sepsis episode |
1 |
| |
|
|
|
|
Total parenteral nutrition via Hickmann catheter because of slow transit bowel, intestinal pseudo obstruction, or gastroparesis |
3 |
Anidulafungin and step down to fluconazol |
3 |
Died due to infectious complications 71 or 15 days after initiation of IFN-γ therapy |
2 |
|
Placebo treated patients | ||||||||||
| 53.0 ± SD19.1 |
C. glabrata |
2 |
Candidaemia |
3 |
Total parenteral nutrition via Hickmann catheter because of slow transit bowel |
1 |
Anidulafungin |
2 |
Cured without further infectious complications |
3 |
|
BMI |
C. tropicalis |
1 |
|
|
HIV with porth-a-cath for venous access |
1 |
Anidulafungin + amphotericin B |
1 |
|
|
| 18.5 ± SD4.0 |
|
|
|
|
construction of ileal conduit urinary diversion (Bricker deviation) because of pT4N2M1 bladder cancer. |
1 |
|
|
|
|
|
Gender |
|
|
|
|
|
|
|
|
|
|
| F: 3 M: 0 | ||||||||||
F, female; M, male; ICD, implantable cardioverter-defribillator; HIV, human immunodeficiency virus; L-AMB, liposomal amphotericin B; BAL, bronchoalveolar lavage; AML, acute myeloid leukemia.